Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery.
Plague is a zoonotic disease caused by Yersinia pestis, an etiological agent of pneumonic and bubonic plague. There is a need for an improved plague vaccine that may overcome the limitation of presently available whole cell vaccine. An alternative approach described here, is the use of protective epitopes from immunodominant antigen of Y. pestis. One such antigen is the F1 antigen, a major envelope and virulent protein that possess antiphagocytic and anti-microbial properties. The present study was aimed to develop a peptide-based vaccine, based upon the constructs made between B and T cell epitopes of F1 antigen of Y. pestis. The immunogenicity, IgG subclass pattern, affinity, avidity and in vivo protective efficacy of the antibodies generated for different B-T constructs were studied in murine model using microsphere as the delivery vehicle. The mode of immunization was both intranasal and intramuscular, with single and multiple doses of immunization, respectively. Intranasal immunization generated consistent high titre and long lasting immune response both for IgG and IgA in sera and sIgA in washes while intramuscular route generated peak IgG levels in sera only. The IgG isotypic levels pattern showed higher IgG2a/IgG2b levels in intranasal route while mixed isotypic levels of IgG1, IgG2a/IgG2b were observed in intramuscular route. The affinity and relative avidity of antibodies showed best results with intranasal route as compared to the intramuscular route. The specific activity measurement (IgG/IgA content) in sera and washes were well correlated with the antibody levels. Finally, in vivo protective studies showed that B1T1 and B2T1 conjugates protected the mice till day 15 while rest of the conjugates showed poor protection.
Tripathi
Vinita
V
Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029, India.
Chitralekha
K T
KT
Bakshi
Anand R
AR
Tomar
Deepak
D
Deshmukh
R A
RA
Baig
M A
MA
Rao
D N
DN
D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000915:Antibody Affinity; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D018985:Epitopes, B-Lymphocyte / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D005260:Female; D018928:Immunity, Mucosal; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D007273:Injections, Intramuscular; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D010930:Plague / Q000276:immunology / Q000517:prevention & control*; D010931:Plague Vaccine / Q000276:immunology*; D016019:Survival Analysis; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D018985:Epitopes, B-Lymphocyte; D018984:Epitopes, T-Lymphocyte; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D010931:Plague Vaccine; D014614:Vaccines, Synthetic; C086725:caf1 protein, Yersinia pestis